Icon is used for the micro-invasive treatment of smooth surface and proximal caries lesions.? It can be used to treat lesions into the first third of dentin (D-1).? In one patient visit, and with no drilling, Icon can arrest the progression of early enamel lesions (caries) and white spot caries-like lesions
Icon represents an entirely new, revolutionary approach to treatment of incipient caries ? a caries infiltrant. This breakthrough micro-invasive technology fills and reinforces demineralized enamel without drilling or anesthesia.
Failure of Previous treatments fall short because:
- Fluoride therapy?? not always effective in the advanced stages
- Filling?almost always sacrifices significant amounts of healthy tooth structure
Composition
- Icon-Etch: Hydrochloric acid, pyrogenic silic – ic acid, surface-active substances
- Icon-Dry: 99% ethanol
- Icon-Infiltrant: Methacrylate-based resin matrix, initiators, additives
INDICATIONS:
- Micro-invasive treatment of non-cavitated dental enamel lesions
- Micro-invasive treatment of non-cavitated dental enamel lesions
CONTRAINDICATIONS:
Do not use this material: ? for deeper seated lesions (D2 ? D3) or on cavitated enamel (enamel defects)
In case of known allergies to any material component or existing contact allergies.
ADVANTAGES:
Icon provides an innovative, never-before-seen option for treatment of smooth surface and proximal carious lesions.
Instead of taking a ?wait and see? approach, Icon can arrest the progress of early enamel lesions up to the first third of dentin ? in one simple procedure, without unnecessary loss of healthy tooth structure!
Cosmetically remove white spot lesions in just one visit! ? Icon offers a revolutionary approach to the cosmetic treatment of carious white spot lesions. ? Lesions infiltrated by Icon take on the appearance of the surrounding healthy enamel. This provides a highly esthetic alternative to micro-abrasion and restorative treatments of cariogenic white spots ? all in one simple treatment, with no drilling!
There are no reviews yet.